Printer Friendly

QUIDEL FORMS JOINT DISTRIBUTION VENTURE IN EUROPE

 QUIDEL FORMS JOINT DISTRIBUTION VENTURE IN EUROPE
 SAN DIEGO, Oct. 8 /PRNewswire/ -- QUIDEL Corp. (NASDAQ: QDEL),


today announced the establishment of a joint marketing and distribution venture with Epignost GmbH, one of its major European distributors. This new company, called QUIDEL/EPIGNOST Ventures GmbH, will be headquartered in Linz, Austria.
 In addition to establishing a QUIDEL corporate presence in Europe, this important enterprise focuses on the expanded marketing and distribution of all QUIDEL and Epignost products into new territories within Europe and the Middle East.
 "This joint venture allows QUIDEL to manufacture products for new territories within and outside of Europe, while giving Epignost the opportunity to market innovative technologies in these same new territories," said Rudolf Hellmayr, director of sales and marketing at Epignost.
 "The establishment of this new company highlights the growing importance of the expanding worldwide markets for diagnostic products and positions QUIDEL to be a leading supplier into these new areas," said Scott L. Glenn, chairman and chief executive officer at QUIDEL. "We currently have a presence in key European and Asian markets through our strategic partners; however, there are several untapped and rapidly developing markets. With our strong existing and new product pipeline teamed with Epignost's proven distribution capabilities we should accelerate the growth of our international business."
 Epignost is an Austrian company active in the field of parenterals and diagnostics. The diagnostic field includes tests for allergens, autoimmune diseases and infectious diseases. The diagnostic program is designed for both the doctor's office with rapid dipstick tests and the reference laboratory with IFA and ELISA assays.
 QUIDEL Corp. develops, manufactures, and markets rapid immunodiagnostic products that provide simple, accurate, and cost- effective diagnoses in the areas of human fertility, infectious disease, allergy and autoimmune disorders. These tests are designed for use in the physician's office, clinical laboratory and home testing markets.
 -0- 10/8/92
 /CONTACT: Mark Francois, manager, investor relations of QUIDEL, 619-552-7931; or Anthony J. Russo, of Noonan/Russo Communications, 212-979-9180, for QUIDEL/
 (QDEL) CO: QUIDEL Corp.; Epignost GmbH; QUIDEL/EPIGNOST Ventures GmbH ST: California IN: MTC SU: JVN


KJ-ML -- SD003 -- 7718 10/08/92 08:00 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1992
Words:355
Previous Article:NATURE FOOD CENTRES ANNOUNCES SEPTEMBER SALES INCREASE OF 17.8 PERCENT
Next Article:SPI PHARMACEUTICALS INTRODUCES HEART DRUG IN MEXICO
Topics:


Related Articles
QUIDEL RECEIVES U.S PATENT WHICH WILL EXPAND ITS FERTILITY FRANCHISE
QUIDEL NETS MORE THAN $2 MILLION FROM EXERCISE OF WARRANTS
QUIDEL EXPANDS EUROPEAN DISTRIBUTION; SIGNS PRODUCT LICENSING AGREEMENT FOR POLISH MARKET
QUIDEL AND BECTON DICKINSON SIGN NEW AGREEMENT - QUIDEL ACQUIRES RIGHTS TO CONSUMER FERTILITY PRODUCTS
QUIDEL REPORTS INCREASED SECOND QUARTER SALES; QUIDEL BRANDED PRODUCT SALES INCREASE 30 PERCENT
QUIDEL REPORTS THIRD QUARTER RESULTS
QUIDEL Reports 39% Sales Increase And Significantly Increased Earnings For The Fourth Quarter
Frost & Sullivan Bestows the 2005 Growth Strategy Leadership of the Year Award Upon Quidel.
Quidel Corporation Receives 2005 Growth Strategy Leadership of the Year Award From Frost & Sullivan.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters